Lupin Limited (BOM:500257)
India
· Delayed Price · Currency is INR 1,892.70
-3.05 (-0.16%)
At close: Jul 11, 2025
Lupin Revenue
In the fiscal year ending March 31, 2025, Lupin had annual revenue of 227.08B INR with 13.48% growth. Lupin had revenue of 56.67B in the quarter ending March 31, 2025, with 14.24% growth.
Revenue
227.08B
Revenue Growth
+13.48%
P/S Ratio
3.81
Revenue / Employee
11.82M
Employees
19,210
Market Cap
864.43B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | 151.63B | -2.12B | -1.38% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 9,646.93B |
| HDFC Bank | 2,728.47B |
| Tata Consultancy Services | 2,568.46B |
| Bharti Airtel | 1,729.85B |
| ICICI Bank | 2,006.54B |
| State Bank of India | 3,429.39B |
| Infosys | 1,647.16B |
| Hindustan Unilever | 631.21B |
Lupin News
- 7 days ago - Lupin launches Ipratropium Bromide Nasal Solution (Nasal Spray) in the US market - Business Upturn
- 10 days ago - Lupin gets USFDA nod for Loteprednol Etabonate Ophthalmic Gel; Eligible for 180-day generic exclusivity - Business Upturn
- 10 days ago - Lupin carves out LupinLife into separate consumer healthcare subsidiary to focus on OTC consumer wellness market - Business Upturn
- 26 days ago - Lupin shares in focus as company signs respiratory drug deal in China with Sino Universal - Business Upturn
- 4 weeks ago - Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets - Business Upturn
- 6 weeks ago - Lupin to present Phase 1 data on LNP7457 cancer drug at ASCO 2025 - Business Upturn
- 6 weeks ago - Lupin and SteinCares sign license and supply agreement for Ranibizumab in Latin America - Business Upturn
- 2 months ago - Lupin secures FDA approval for Rivaroxaban 10 mg, 15 mg and 20 mg tablets - Business Upturn